Novel Syngeneic Cell Lines for Studying High-Risk BRAFV600E-Driven Colorectal Cancer <i>In Vivo</i>
We present three newly isolated syngeneic BRAFV600E-driven colorectal cancer cell lines with distinct in vitro and in vivo phenotypes. They differ in their response to drug treatments, resemble patient tumor heterogeneity, and enable efficient tumor growth in immunocompetent mice for tumor-immune microenvironment studies.
Authors
- Rebecca Kesselring (ORCID: https://orcid.org/0000-0001-8131-7605)
- Silke Kowar
- Tilman Brummer (ORCID: https://orcid.org/0000-0003-4387-7905)
- Sebastian Halbach (ORCID: https://orcid.org/0000-0002-6827-8178)
- Lisa Marx (ORCID: https://orcid.org/0000-0002-3900-8451)
- Luigi Nardella (ORCID: https://orcid.org/0009-0002-7142-8787)
- Reinhild Feuerstein (ORCID: https://orcid.org/0000-0002-4437-2194)
- Ian J. Frew (ORCID: https://orcid.org/0000-0003-2735-5509)
- Jasmin Traichel (ORCID: https://orcid.org/0000-0002-5417-022X)
- Ricarda Griffin (ORCID: https://orcid.org/0000-0003-1368-2832)
- Jule Schrimpf
- Nadine Wohlfeil
- Melanie Boerries
- Agnes Lindenthal
- Alina Seger
- Patrick Metzger
- Maria Walz
- Ariane Metzger
- Célia Asdih
Institutions
- University of Freiburg (DE)
- University Medical Center Freiburg (DE)
- University of Education Freiburg (DE)
Publication Details
- Journal
- Cancer Research Communications
- Published
- 2026-01-22
- DOI
- https://doi.org/10.1158/2767-9764.crc-25-0599
- Citations
- 1
- Primary Topic
- Colorectal Cancer Treatments and Studies
- Type
- article
- Field-Weighted Citation Impact
- 24.20